– Tianjin Boyun Purification Equipment Material Technology Co., Ltd., a leading enterprise in the development and manufacturing of chromatographic packing materials/specific separation and extraction materials for the pharmaceutical industry, Suzhou Aijieboya Bioelectronics Technology Co., Ltd., a major leader in the development and manufacture of biomedical automation instruments and equipment/a major leader in Suzhou Industrial Park in 2020, and Zhejiang Boyi Biotechnology Co., Ltd., a manufacturer of industrial chromatography automation equipment, have recently completed their strategic integration. The integration has formed an integrated solution for industrial chromatography separation and purification and automated R&D and production of clinical mass spectrometry pretreatment (hereinafter referred to as “Aijieboya Bio”), and recently completed tens of millions of yuan in Series A financing, which was led by Sany Innovation Investment, a well-known investment institution in the industry, and jointly participated by Oriza Holdings, Tongchuangweiye and Shangshi Investment.
– After the merger, Agilebio has three product development and production bases located in Suzhou Industrial Park, Zhejiang Jiaxing Science and Technology City and Tianjin Binhai New Area, and has established supporting application support and customer service centers throughout the country with Suzhou as the center. The core team members include academicians of the Chinese Academy of Sciences, experts of the National Talent Program, and a number of high-tech personnel from well-known enterprises and institutions at home and abroad. Ajetboya expects to achieve a main business income of more than 80 million yuan in 2022.
– Through the merger, Agilebio has strongly expanded its strategic deployment in the fields of biomedicine and clinical mass spectrometry, integrating leading technologies in separation media, automated fluid control and separation equipment, and drug purification process development to provide extraction and separation products and overall solutions. At present, a number of the company’s original innovative and localized alternative products have been recognized and widely used by many well-known enterprises in the industry, such as: the industrial production of third-generation silica gel matrix chromatography materials, automatic magnetic solid-phase extraction technology for clinical mass spectrometry detection sample pretreatment, etc., to solve the “stuck neck” technical problems for customers.
– Ajet Biotech owns and implements the dual brand strategy of “Agilebio” and “Bioseps Purification“:
The main products include:
Agilebio brand – provides instruments and equipment based on fluid monitoring and automatic control: biological laboratory equipment, biopharmaceutical equipment, IVD automatic instruments
Bioseps Purification—Provide a total solution for industrial purification based on chromatography and specific adsorption: purification media from the laboratory to industrial automation equipment, method development and purification services
For the success of this round of financing, Dr. Wang Qunjie, chairman of Ajetboya Biotech, said: Thank you for being favored by investors in the industry, this investment is in line with the company’s future development strategy, which is conducive to the company’s enhancement of financial strength and the promotion of the company’s core technology and development. Promote the localization process of the company’s biological sample processing, industrial chromatography separation and purification packing and process automation equipment, and further enhance the company’s overall competitiveness in biomedicine, IVD and other industries.
About Sany Innovation Investment: Sany Innovation (Beijing) Investment Management Co., Ltd. (“Sany Innovation Investment”) is a private equity venture capital firm focusing on pharmaceutical innovation, with fund investors including well-known enterprises in the pharmaceutical industry and well-known investment institutions in the financial field. Adhering to the belief of “scientists, professional managers, investors, the trinity, professional people do professional things, and serve health with science”, Sany Innovation Investment integrates resources through capital ties, supports scientists to realize the transformation of scientific research achievements, helps professional managers build an entrepreneurial platform, and achieves a number of innovative biomedical enterprises, so that science can serve health and benefit patients. Sany Innovation Investment is committed to growing together with its portfolio companies and entrepreneurs, and uses industry experience and resources to help its portfolio companies maximize their technological value.
About Oriza Holdings: Since its establishment in 2001, Oriza Holdings has focused on the field of equity investment, with a fund scale of over 100 billion yuan under management, and is one of the leading equity investment institutions in China. Since its establishment, it has focused on investment opportunities in emerging industries such as integrated circuits, biomedicine, artificial intelligence, and nanotechnology applications, and insisted on supporting real industries to promote industrial transformation and upgrading. At present, there are more than 1,100 direct investment projects, and Oriza FOF has invested in 147 sub-funds.
About Tongchuangweiye: Tongchuangweiye is the first batch of local investment institutions in China, with a cumulative asset scale of more than 30 billion yuan, more than 500 investment enterprises, and has successfully promoted the IPO or M&A listing of nearly 100 enterprises, and has invested in more than 100 enterprises in the medical field, and more than 20 IPOs or mergers and acquisitions.
About Shangshi Capital: Founded in 2014, Shangshi Capital is headquartered in Beijing with offices in Shenzhen and San Francisco. Shangshi Capital currently manages two USD funds and three RMB funds, with assets under management equivalent to more than RMB 1.5 billion, and the RMB funds have been filed with the Asset Management Association of China. Shangshi Capital’s current investment stage covers seed round to Series B round, with key investment areas in digital health and wellness, consumption upgrading, artificial intelligence, IOT and enterprise services. Beijing Shangshi Investment Center was registered in June 2014 with a registered capital of 220 million yuan, and was filed with the Asset Management Association of China on October 27, 2016, and now invests in 19 start-up enterprises.
About Agilebio Biotech: Relying on separation materials, fluid automation technology, and online testing technology, we are committed to the development of new materials and automation systems in the fields of biomedicine, clinical testing, and food testing. Relying on industrial separation and purification products and services based on chromatography and specific adsorption, we are committed to providing overall solutions for extraction, separation and purification for biomedical customers.
It has achieved a breakthrough in the industrialization of the large-scale production of third-generation silica gel matrix chromatography materials, and has many new products of special chromatographic separation and adsorption materials, such as polar, alkali-resistant, hydrophilic and other organic bonded silica gels, protein confinement, core-shell, magnetic solid-phase extraction and other chromatographic media, and specific adsorption materials such as trace metals, endotoxins, organic toxins, and phospholipid proteins in biological samples, which have reached the international mainstream product level in terms of quality and stability, and have significant advantages in price.
From laboratory to industrial automation, the purification equipment is complete. Intelligent and automated industrial chromatography separation and purification equipment has innovative designs such as online monitoring, online liquid preparation, and online solvent recovery, which fully meet the standards of the pharmaceutical industry.
The self-developed and produced mSPE automatic magnetic bead extraction technology and products have assisted many institutions to apply for clinical mass spectrometry detection products and projects such as “catecholamine metabolites”, “hormones” and “vitamins”. Up to now, some institutions have successfully completed the application and obtained relevant qualification certification.
Agilebio has a technical and management team that includes academicians of the Chinese Academy of Sciences, experts of the National Talent Program, and a number of high-tech personnel from well-known enterprises and institutions at home and abroad. The company has obtained or applied for more than 60 intellectual property rights, including invention patents, utility model patents, software copyrights and so on. The company has passed the ISO9001 quality management system certification, and its products have obtained a number of qualification certifications including IP54, IP20, CE (LVD, EMC, ROHS), and medical devices.
List of Agilebio institutions:
Follow us
Complete sets of industrial chromatography purification processes and solutions
Gram to kilogram purification preparation services
Complete sets of separation and purification process equipment that meet GMP requirements
Industrial chromatography separation packings
New extraction and purification materials for laboratory and industrial production
Biomedicine, clinical testing and other sample pretreatment materials, testing kits and supporting automation systems
